Healthcare -
Biotechnology - NASDAQ - US
$ 5.64
0.714 %
$ 493 M
Market Cap
-5.22
P/E
1. INTRINSIC VALUE
Balance Sheet
Terns Pharmaceuticals, Inc.
| Current Assets | 362 M |
| Cash & Short-Term Investments | 358 M |
| Receivables | 0 |
| Other Current Assets | 3.94 M |
| Non-Current Assets | 1.82 M |
| Long-Term Investments | 0 |
| PP&E | 1.47 M |
| Other Non-Current Assets | 350 K |
| Current Liabilities | 15.6 M |
| Accounts Payable | 2.15 M |
| Short-Term Debt | 428 K |
| Other Current Liabilities | 13.1 M |
| Non-Current Liabilities | 2.41 M |
| Long-Term Debt | 919 K |
| Other Non-Current Liabilities | 1.49 M |
EFFICIENCY
Earnings Waterfall
Terns Pharmaceuticals, Inc.
| Revenue | 0 |
| Cost Of Revenue | 0 |
| Gross Profit | 0 |
| Operating Expenses | 102 M |
| Operating Income | -102 M |
| Other Expenses | -13 M |
| Net Income | -88.9 M |
RATIOS
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis
Terns Pharmaceuticals, Inc.
| Net Income | -88.9 M |
| Depreciation & Amortization | 896 K |
| Capital Expenditures | -42 K |
| Stock-Based Compensation | 15.6 M |
| Change in Working Capital | 4.38 M |
| Others | 2.66 M |
| Free Cash Flow | -70.1 M |
Wall Street Analysts Price Targets
Terns Pharmaceuticals, Inc.
Wall Street analysts predict an average 1-year price target for TERN of $18.7 , with forecasts ranging from
a
low of
$10 to a high of $26 .
TERN Lowest Price Target
Wall Street Target
10 USD
77.30%
TERN Average Price Target
Wall Street Target
18.7 USD
230.97%
TERN Highest Price Target
Wall Street Target
26 USD
360.99%
4. DIVIDEND
ANALYSIS
TERN does not distribute dividends.
5. COMPETITION
6. Ownership
Insider Ownership
Terns Pharmaceuticals, Inc.
Sold
0-3 MONTHS
3.64 K USD 1
3-6 MONTHS
2.37 K USD 1
6-9 MONTHS
211 K USD 3
9-12 MONTHS
396 K USD 2
Bought
187 K USD 2
0-3 MONTHS
0 USD 0
3-6 MONTHS
125 K USD 2
6-9 MONTHS
5 M USD 1
9-12 MONTHS
7. News
Terns Pharmaceuticals: A Risky Buy Ahead Of Q4 Obesity, Oncology Catalysts
Terns Pharmaceuticals, Inc. offers two differentiated late-stage assets—TERN-701 for CML and TERN-601 for obesity—with major data catalysts expected in Q4 2025. TERN-701 shows early signs of best-in-class potential in CML, with encouraging molecular response and safety data versus Novartis' Scemblix. TERN-601's oral GLP-1 candidate demonstrated promising weight loss and tolerability, targeting a massive obesity market with room for differentiated entrants.
seekingalpha.com
- 1 week ago
Terns Pharmaceuticals Presents Positive Data from Phase 1 Study of TERN-601 Once-daily Oral GLP-1R Agonist for Treatment of Obesity at 85th Annual American Diabetes Association Scientific Sessions
Phase 1 clinical study of TERN-601 demonstrated differentiated profile in 28-day study; topline data were presented in September 2024
globenewswire.com
- 1 month ago
3 Penny Stocks Wall Street Sees With 243% Upside
“The Next NVIDIA” Could Change Your Life NVIDIA has returned 250-fold in the past 10 years as artificial intelligence took off.
247wallst.com
- 1 month ago
Squarepoint Ops LLC Has $73,000 Holdings in Terns Pharmaceuticals, Inc. (NASDAQ:TERN)
Squarepoint Ops LLC cut its holdings in Terns Pharmaceuticals, Inc. (NASDAQ:TERN – Free Report) by 75.5% during the 4th quarter, according to its most recent disclosure with the SEC. The institutional investor owned 13,125 shares of the company’s stock after selling 40,393 shares during the period. Squarepoint Ops LLC’s holdings in Terns Pharmaceuticals were worth $73,000 as of its most recent filing with the SEC. Several other institutional investors and hedge funds have also modified their holdings of the business. Tema Etfs LLC acquired a new position in shares of Terns Pharmaceuticals in the fourth quarter valued at about $442,000. Sherbrooke Park Advisers LLC acquired a new position in shares of Terns Pharmaceuticals in the fourth quarter valued at about $99,000. ProShare Advisors LLC grew its stake in shares of Terns Pharmaceuticals by 58.4% in the fourth quarter. ProShare Advisors LLC now owns 23,821 shares of the company’s stock valued at $132,000 after acquiring an additional 8,784 shares in the last quarter. Parkman Healthcare Partners LLC grew its stake in shares of Terns Pharmaceuticals by 51.9% in the fourth quarter. Parkman Healthcare Partners LLC now owns 829,105 shares of the company’s stock valued at $4,593,000 after acquiring an additional 283,354 shares in the last quarter. Finally, Nuveen Asset Management LLC grew its stake in shares of Terns Pharmaceuticals by 30.6% in the fourth quarter. Nuveen Asset Management LLC now owns 2,633,918 shares of the company’s stock valued at $14,592,000 after acquiring an additional 617,009 shares in the last quarter. 98.26% of the stock is currently owned by institutional investors and hedge funds. Analysts Set New Price Targets Several research firms recently commented on TERN. William Blair restated a “market perform” rating on shares of Terns Pharmaceuticals in a research note on Friday, March 21st. JMP Securities reiterated a “market outperform” rating and set a $20.00 price objective on shares of Terns Pharmaceuticals in a research note on Monday, April 21st. Finally, BMO Capital Markets reduced their price objective on shares of Terns Pharmaceuticals from $26.00 to $15.00 and set an “outperform” rating on the stock in a research note on Tuesday, May 13th. Two equities research analysts have rated the stock with a hold rating and three have issued a buy rating to the stock. According to MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average target price of $15.63. View Our Latest Analysis on Terns Pharmaceuticals Terns Pharmaceuticals Stock Up 9.4% Shares of Terns Pharmaceuticals stock opened at $4.06 on Wednesday. The company has a market capitalization of $354.59 million, a price-to-earnings ratio of -3.44 and a beta of -0.18. Terns Pharmaceuticals, Inc. has a 12-month low of $1.87 and a 12-month high of $11.40. The firm’s 50-day moving average price is $2.90 and its two-hundred day moving average price is $4.06. Terns Pharmaceuticals (NASDAQ:TERN – Get Free Report) last announced its quarterly earnings data on Thursday, May 8th. The company reported ($0.26) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.29) by $0.03. On average, sell-side analysts expect that Terns Pharmaceuticals, Inc. will post -1.19 earnings per share for the current year. Terns Pharmaceuticals Company Profile (Free Report) Terns Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops small-molecule product candidates for the treatment of oncology, metabolic dysfunction-associated steatohepatitis (MASH), and obesity. The company develops TERN-701, an allosteric BCR-ABL tyrosine kinase inhibitor (TKI) that is in phase 1 clinical trial for chronic myeloid leukemia (CML), a form of cancer that starts in bone marrow.
https://www.defenseworld.net
- 1 month ago
Terns Pharmaceuticals to Participate in Upcoming June Investor Conferences
FOSTER CITY, Calif., May 29, 2025 (GLOBE NEWSWIRE) -- Terns Pharmaceuticals, Inc. (“Terns” or the “Company”) (Nasdaq: TERN), a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity, today announced that members of senior management will be participating in the following upcoming investor conferences in June.
globenewswire.com
- 1 month ago
Terns Pharmaceuticals Selected for Oral Presentation at European Hematology Association Congress For Preclinical Data on Novel Allosteric BCR-ABL Inhibitor TERN-701
Preclinical data highlight improved potency vs. asciminib across multiple clinically relevant variants of BCR-ABL including difficult-to-treat resistance mutations
globenewswire.com
- 2 months ago
Terns Pharmaceuticals Reports First Quarter 2025 Financial Results and Provides Corporate Updates
Initiated dose expansion in Phase 1 CARDINAL trial of TERN-701 in 2L+ CML Additional safety and efficacy data including 6-month MMR expected in 4Q25 Phase 2 FALCON trial of TERN-601 for obesity is enrolling well with top-line 12-week weight loss data expected in 4Q25 FOSTER CITY, Calif., May 08, 2025 (GLOBE NEWSWIRE) -- Terns Pharmaceuticals, Inc. (“Terns” or the “Company”) (Nasdaq: TERN), a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity, today reported financial results for the first quarter ended March 31, 2025, and provided corporate updates.
globenewswire.com
- 2 months ago
Terns Pharmaceuticals Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(C)(4)
FOSTER CITY, Calif., May 02, 2025 (GLOBE NEWSWIRE) -- Terns Pharmaceuticals, Inc. (“Terns” or the “Company”) (Nasdaq: TERN), a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity, today announced that it has granted as of May 1, 2025 equity inducement awards to two new employees under the terms of the 2022 Employment Inducement Award Plan, as amended. The equity awards were approved by the Compensation Committee of the Company's Board of Directors in accordance with Nasdaq Listing Rule 5635(c)(4) and were made as a material inducement to the employees' acceptance of employment with Terns.
globenewswire.com
- 2 months ago
Terns Pharmaceuticals to Participate in The Citizens Life Sciences Conference
FOSTER CITY, Calif., April 30, 2025 (GLOBE NEWSWIRE) -- Terns Pharmaceuticals, Inc. (“Terns” or the “Company”) (Nasdaq: TERN), a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity, today announced that members of senior management will be participating in a fireside chat at The Citizens Life Sciences Conference on Wednesday, May 7, 2025 at 2:30 p.m. ET.
globenewswire.com
- 2 months ago
Down -39.83% in 4 Weeks, Here's Why Terns Pharmaceuticals (TERN) Looks Ripe for a Turnaround
Terns Pharmaceuticals (TERN) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.
zacks.com
- 3 months ago
Down -31.41% in 4 Weeks, Here's Why You Should You Buy the Dip in Terns Pharmaceuticals (TERN)
Terns Pharmaceuticals (TERN) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.
zacks.com
- 3 months ago
Terns Pharmaceuticals Reports Inducement Grant to New Employees Under Nasdaq Listing Rule 5635(C)(4)
FOSTER CITY, Calif., April 02, 2025 (GLOBE NEWSWIRE) -- Terns Pharmaceuticals, Inc. (“Terns” or the “Company”) (Nasdaq: TERN), a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity, today announced that it has granted as of April 1, 2025 an equity inducement award to two new employees under the terms of the 2022 Employment Inducement Award Plan, as amended. The equity awards were approved by the Compensation Committee of the Company's Board of Directors in accordance with Nasdaq Listing Rule 5635(c)(4) and were made as a material inducement to the employees' acceptance of employment with Terns.
globenewswire.com
- 3 months ago
8. Profile
Summary
Terns Pharmaceuticals, Inc. TERN
COUNTRY
US
INDUSTRY
Biotechnology
MARKET CAP
$ 493 M
Dividend Yield
0.00%
Description
Terns Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops small-molecule single-agent and combination therapy candidates for the treatment of non-alcoholic steatohepatitis (NASH) and obesity. The company develops TERN-101, a liver-distributed and non-bile acid farnesoid X receptor agonist, which is in Phase IIa clinical trial for the treatment of NASH; and TERN-201, a vascular adhesion protein-1 inhibitor that is in Phase Ib clinical trial for the treatment of NASH. It also develops TERN-501, a thyroid hormone receptor beta agonist with enhanced liver distribution and metabolic stability that is in Phase I clinical trial for the treatment of NASH; and TERN-601, a small-molecule Glucagon-Like Peptide-1 receptor agonist program that is intended to orally be administered for NASH and metabolic diseases, such as obesity. The company was incorporated in 2016 and is headquartered in Foster City, California.
Contact
1065 East Hillsdale Boulevard, Foster City, CA, 94404
https://www.ternspharma.com
IPO
Date
Feb. 5, 2021
Employees
59
Officers
Dr. Emil T. Kuriakose M.D.
Chief Medical Officer
Ms. Yasameen Qazen
Senior Vice President of Regulatory Affairs & Quality Assurance
Mr. James Kanter
Senior Vice President of CMC
Mr. David Eric Strauss
Vice President of Finance & Controller
Ms. Amy L. Burroughs M.B.A.
Chief Executive Officer & Director
Ms. Melita Sun Jung
Chief Business Officer
Mr. Andrew W. Gengos
Chief Financial Officer
Dr. Jeffrey R. Jasper Ph.D.
Senior Vice President of Research
Mr. Scott Harris
Chief Development Officer
Ms. Debra Sieminski
Senior Vice President of Medical Affairs